In this study, we found that there were significant differences in the activation of pathways in different DDR groups in HCC cohorts, and DDR1 patients had low expression of DDR-related genes, while DDR2 patients had high expression of DDR-related genes. This evidence concerns the gene DDR2 and hepatocellular carcinoma.